Corticosteroid treatment for fibrotic hypersensitivity pneumonitis
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether taking a corticosteroid (a type of anti-inflammatory medicine) for six months can help people with fibrotic hypersensitivity pneumonitis, a lung disease that causes scarring and makes it hard to breathe. The study compares the drug to a placebo (a pill with no active medicine) to see if it improves lung function or slows down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have a confirmed diagnosis of fibrotic hypersensitivity pneumonitis, which is a lung condition caused by breathing in substances like mold or dust that leads to scarring in the lungs.
- Your CT scan shows scarring (fibrosis) in at least 10% of your lungs.
- Your lung function is not too severely reduced, with certain breathing test scores at or above 50% and 30%.
- You have not taken steroids, immune-suppressing drugs, or anti-fibrotic medications for this condition before.
- You are not pregnant or breastfeeding, and you are not eligible for state medical assistance (AME) in France.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special home visit from an indoor environment medical advisor can help people with fibrosing hypersensitivity pneumonitis. The goal is to find and address things in your home that might be making your lung condition worse.
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
This trial tests an inhaled medication for COPD. It aims to see if the treatment is safe and helps improve breathing and symptoms.
Hear when a new Hypersensitivity Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.